Alicia Iruzun Lafitte, Partner at UCB Ventures, Boston, Massachusetts, United States — verified investor profile. See sector focus and contact routes.
Alicia Irurzun-Lafitte serves as a Partner at UCB Ventures, the corporate venture arm of biopharmaceutical company UCB, having joined the firm in Boston in March 2019 after departing from a principal role at M Ventures, Merck KGaA’s corporate venture unit. Her investment focus centers on oncology, immunology, and women’s health, with activity spanning both the United States and Europe, reflecting her prior work closing multiple investments in these sectors at M Ventures. While specific check sizes and lead/follow behavior are not publicly disclosed, her background includes instrumental involvement in building spin-offs and executing strategic corporate development transactions at Merck Serono and EMD Serono. Notable portfolio companies linked to her tenure include GlycoMimetics and Fluidigm, which UCB Ventures invested in during the period she joined. Switch Therapeutics also lists her as a board member, indicating an active role in at least one venture. No distinctive public writing or unique point of view from Irurzun-Lafitte is documented in available sources, and her public profile remains focused on her operational role within UCB Ventures.
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Boston.
Investors like Alicia Iruzun Lafitte · Full investor directory · Investor access · Company funding database